European Medical Solutions
ALEMS
Company Profile
Business description
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
Contact
7 Rue des Chasseurs Ardennais
Liege4031
BELT: +32 471563533
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
127
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,961.50 | 44.10 | -0.49% |
| CAC 40 | 8,385.49 | 44.78 | 0.54% |
| DAX 40 | 24,740.36 | 153.22 | -0.62% |
| Dow JONES (US) | 51,848.90 | 182.06 | 0.35% |
| FTSE 100 | 10,461.63 | 32.78 | 0.31% |
| HKSE | 23,090.27 | 321.91 | -1.37% |
| NASDAQ | 25,476.64 | 110.40 | -0.43% |
| Nikkei 225 | 72,080.43 | 2,905.46 | 4.20% |
| NZX 50 Index | 13,493.31 | 92.65 | 0.69% |
| S&P 500 | 7,358.22 | 7.24 | -0.10% |
| S&P/ASX 200 | 8,760.30 | 40.30 | -0.46% |
| SSE Composite Index | 4,125.76 | 14.94 | 0.36% |